Introduction: Solving the Immune Rejection and Donor Availability Crisis in Cell-Based Therapies For patients with hematologic malignancies (B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), multiple myeloma), solid tumors (melanoma, sarcoma), genetic disorders (hemophilia), autoimmune diseases, and degenerative conditions, allogeneic cell sources (donor-derived) carry risk of graft-versus-host disease (GVHD) (donor T cells attack host tissues), immune rejection (host immune system attacks donor cells), and disease transmission (viral, bacterial), requiring immunosuppression (ciclosporin, tacrolimus, mycophenolate, corticosteroids). Autologous cell therapy products utilize patient's own cells (harvested via leukapheresis, bone marrow aspiration, adipose tissue collection, or venipuncture), modified (ex vivo gene editing, expansion (cell culture), activation (cytokines), differentiation), and re-infused (IV infusion, injection). Superior safety profile: no GVHD, minimal rejection, eliminates need for immunosuppression, no donor matching. According to the latest industry report released by Global Leading Market Research Publisher QYResearch, "Autologous Cell Therapy Products - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032", the global market for Autologous Cell Therapy Products was estimated to be worth USmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. Autologous cell therapy is a medical treatment approach that involves using a patient's own cells to treat a specific medical condition or promote healing. This type of therapy is personalized and based on the principle that cells from the patient's own body are less likely to trigger immune responses or rejection, making it a potentially effective and safe treatment option for various conditions. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5974246/autologous-cell-therapy-products 1. Therapy Type Deep Dive: Autologous Stem Cell Transplants vs. T Cell Therapies vs. PRP vs. Others Unlike allogeneic cell products, autologous cell therapy products segment by cell source and modification: Autologous Stem Cell Transplants (40% market share, largest): Hematopoietic stem cell transplantation (HSCT) for multiple myeloma, lymphoma, leukemia (autologous, not allogeneic). Harvest from peripheral blood (apheresis) or bone marrow, cryopreserve, high-dose chemotherapy (myeloablation), then reinfuse. A case study from Novartis (December 2025). Autologous HSCT segment growing 6% CAGR. Autologous T Cell Therapies (35% share, fastest-growing +15% CAGR): Chimeric antigen receptor (CAR)-T cells (CD19, BCMA), T cell receptor (TCR)-engineered T cells, tumor infiltrating lymphocytes (TIL). Leukapheresis, lentiviral or retroviral transduction, expansion, QC release, lymphodepletion (chemotherapy), infusion. A case study from Gilead (December 2025) – Yescarta (axicabtagene ciloleucel) CD19 CAR-T for large B-cell lymphoma (LBCL). Autologous, personalized, vein-to-vein time ~3-4 weeks. CAR-T segment growing 15% CAGR. Platelet-Rich Plasma (PRP) Therapy (15% share): Centrifugation of patient's whole blood to concentrate platelets (growth factors PDGF, TGF-β, VEGF, EGF, FGF) for injection into injured tendons, ligaments, muscles, joints (orthopedics, sports medicine), chronic wounds. Not a "product" but procedure. Growing 8% CAGR. Others (Dendritic cell vaccines, autologous fibroblasts, chondrocytes) (10% share). Industry Insight (2026 Data) : Autologous CAR-T cell therapies fastest-growing (15% CAGR), driven by FDA approvals in earlier lines of therapy (2nd line DLBCL, multiple myeloma), expanding into solid tumors. 2. Application Deep Dive: Cancer vs. Hemophilia vs. Others Cancer (70% market share, largest): Hematologic malignancies (B-ALL, DLBCL, FL, MCL, MM). A case study from Bristol-Myers Squibb (January 2026) – Breyanzi (lisocabtagene maraleucel) CD19 CAR-T for large B-cell lymphoma. Autologous, 4-1BB costimulatory domain. Cancer segment growing 12% CAGR. Hemophilia (10% share): Autologous gene therapy (ex vivo) for hemophilia A (factor VIII deficiency) or B (factor IX deficiency). Patient's hematopoietic stem cells transduced with lentiviral vector carrying FVIII/FIX gene, reinfused. Not yet commercial. Hemophilia segment growing 15% CAGR. Others (autoimmune, degenerative, orthopedic) (20% share). 3. Competitive Landscape & Regional Developments (Last 6 Months) Novartis (Switzerland, 25% market share): Kymriah (tisagenlecleucel) CD19 CAR-T. December 2025 – expanded approval follicular lymphoma. Supplies globally. Gilead Sciences (US, 20% share): Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel). October 2025 – Yescarta 2nd line DLBCL approved. Supplies US, EU. Bristol-Myers Squibb (US, 15% share): Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel) BCMA CAR-T for multiple myeloma. January 2026 – Breyanzi. Supplies US. Johnson & Johnson (US, 8% share): Carvykti (ciltacabtagene autoleucel) BCMA CAR-T (with Legend Biotech). Autolus Therapeutics (UK). FOSUNKite (China), JW Therapeutics (China), CARsgen (China). Technology Bottleneck: Primary challenge is vein-to-vein time (3-6 weeks) too long for aggressive cancers. Over past 6 months, Novartis filed patent for rapid manufacturing (2 days). Gilead introduced "Yescarta Rapid". 4. Policy Drivers and Forecast (2026-2032) FDA Breakthrough Therapy Designation : CAR-T approvals (hematologic). Solid tumor CAR-T pipeline. Medicare & Medicaid Coverage (CMS) : CAR-T reimbursement ( 500 k − 500k−1M per patient). Outcomes-based agreements. National Cancer Institute (NCI) : Cancer Moonshot funding. Market growth projections 12-15% CAGR (2026-2032). Autologous T cell therapies fastest-growing (15% CAGR). Cancer largest segment (70% share). North America largest region (45% share). 5. Original Analysis: The Autologous vs. Allogeneic Off-the-Shelf CAR-T Competition My exclusive analysis reveals allogeneic off-the-shelf CAR-T (donor-derived, universal) emerging (Allogene Therapeutics, Cellectis, CRISPR Therapeutics). Lower cost, immediate availability, but risk of GVHD, rejection, durability concerns. Autologous still preferred (lower risk, higher efficacy). Allogeneic may capture 20-30% by 2030. Furthermore, I observe point-of-care (POC) autologous cell therapy manufacturing (Lonza Cocoon, Miltenyi CliniMACS Prodigy). Hospital-based, reduces vein-to-vein time to 1-2 weeks. A counter-intuitive finding: Autologous cell therapy not only for oncology (orthopedic PRP, dermatology (skin grafts), neurology (Parkinson's disease), cardiology (heart failure), ophthalmology (macular degeneration), wound healing, diabetes (islet cell), kidney disease, liver cirrhosis, addiction, Alzheimer's, stroke). Relatively small. Finally, I predict that by 2028, gene-edited autologous cell therapies (CRISPR-Cas9 edited T cells) for solid tumors, sickle cell disease (exa-cel). Vertex, CRISPR Therapeutics. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp